It is essential to develop new carriers for laryngeal drug delivery in light of the lack of therapy in laryngeal related diseases.When the inhalable micron-sized crystals of γ-cyclodextrin metal-organic framework (CD-MOF) was utilized as dry powder inhalers (DPIs) carrier with high fine particle fraction (FPF),it was found in this research that the encapsulation of a glycoside compound,namely,scutellarin (SCU) in CD-MOF could significantly enhance its laryngeal deposition.Firstly,SCU loading into CD-MOF was optimized by incubation.Then,a series of characterizations were carried out to elucidate the mechanisms of drug loading.Finally,the laryngeal deposition rate of CD-MOF was 57.72 ± 2.19％ improved by SCU,about two times higher than that of CD-MOF,when it was determined by Next Generation Impactor (NGI) at 65 L/min.As a proof of concept,pharyngolaryngitis therapeutic agent dexamethasone (DEX) had improved laryngeal deposition after being co-encapsulated with SCU in CD-MOE The molecular simulation demonstrated the configuration of SCU in CD-MOF and its contribution to the free energy of the SCU@CD-MOF,which defined the enhanced laryngeal anchoring.In conclusion,the glycosides-like SCU could effectively enhance the anchoring of CD-MOF particles to the larynx to facilitate the treatment of laryngeal diseases.